EF Hutton Initiates Coverage On VolitionRX with Buy Rating, Announces Price Target of $4.5
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tim Moore has initiated coverage on VolitionRX (AMEX:VNRX) with a Buy rating and a price target of $4.5.
October 30, 2023 | 2:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton has initiated coverage on VolitionRX with a Buy rating and a price target of $4.5, which could positively impact the stock's performance.
The initiation of coverage by EF Hutton, a well-known financial institution, with a Buy rating indicates a positive outlook for VolitionRX. The price target of $4.5 also suggests that the analyst sees potential for the stock's price to increase. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100